Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA6OU0
|
|||
| Drug Name |
GL-ONC1
|
|||
| Synonyms |
olvimulogene nanivacirepvec
Click to Show/Hide
|
|||
| Drug Type |
Oncolytic virus therapy
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1], [2] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [3] | ||
| Peritoneal carcinomatosis [ICD-11: 2D91] | Phase 1/2 | [2] | ||
| Peritoneal cavity cancer [ICD-11: 2C51.Z] | Phase 1 | [1] | ||
| Company |
Genelux
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02759588) GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.